TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16292641

Group type: EXPERIMENTAL
Intervention: Glutamate combined with ketamine (10 mM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glutamate (1 M, 0.2 ml) alone
Number of subjects: 18
Study: 14574094

Group type: EXPERIMENTAL
Intervention: Eight-session intervention
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Four-session intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 11387282

Group type: EXPERIMENTAL
Intervention: Prophylactic salpingectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: No surgical intervention
Number of subjects: 26
Study: 9365148

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg preprandial
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg postprandial
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg postprandial
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8466733

Group type: EXPERIMENTAL
Intervention: Slow-release isradipine (SRO) 2.5 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Slow-release isradipine (SRO) 5 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 3959323

Group type: EXPERIMENTAL
Intervention: 1 liter of 3% amino acid solution daily for 5 days postoperatively
Number of subjects: 22

Group type: COMPARATOR
Intervention: Balanced 5% glucose-containing electrolyte solutions
Number of subjects: 22
Study: 29882884

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 56
Study: 27289472

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily (bid)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Ranitidine 150 mg bid
Number of subjects: 85

Group type: COMPARATOR
Intervention: Comparison of IPA between ranitidine and omeprazole groups after excluding homozygous patients for 2C19*2 genotype
Number of subjects: 85
Study: 24375313

Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Phonation Resistance Training Exercise (PhoRTE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No-treatment control group (CTL)
Number of subjects: 16
Study: 22210078

Group type: EXPERIMENTAL
Intervention: Sutureless amniotic membrane patch with a modified symblepharon ring
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional sutured amniotic membrane patch
Number of subjects: 75
Study: 20537750

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25/75 (LM25)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 580
Study: 18612876

Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia (PCA‐IV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient‐controlled epidural analgesia (PCEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonoperated volunteers
Number of subjects: 60
Study: 16038697

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional CABG on CPB
Number of subjects: 120
Study: 11878685

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg twice a day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 45
Study: 9663539

Group type: COMPARATOR
Intervention: Cold blood cardioplegia (n = 17)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Warm blood hyperkalaemic cardioplegia ('hot shot') (n = 18)
Number of subjects: 35
Study: 7530946

Group type: EXPERIMENTAL
Intervention: TUNA procedure (low-level radiofrequency energy, 4-15 Watts for 3-5 minutes per lesion)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TUNA procedure
Number of subjects: 70
Study: 3136360

Group type: EXPERIMENTAL
Intervention: Outpatient medical detoxification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient medical detoxification
Number of subjects: 0
Study: 1864882

Group type: EXPERIMENTAL
Intervention: MVR with preservation of the posterior leaflet (Group I)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional MVR without preservation of the posterior leaflet (Group II)
Number of subjects: 140
Study: 363480

Group type: EXPERIMENTAL
Intervention: Pindolol monotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pindolol in combination with classical antihypertensives
Number of subjects: 25
Study: 30964178

Group type: EXPERIMENTAL
Intervention: New sex-specific equations to estimate fat mass based on anthropometric parameters
Number of subjects: 38762

Group type: COMPARATOR
Intervention: Cross-validation set
Number of subjects: 38762
Study: 27991835

Group type: EXPERIMENTAL
Intervention: Stimulant medication (lisdexamfetamine 30, 50, or 70 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulant medication (lisdexamfetamine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25403015

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral therapy (ABBT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 64
Study: 23181686

Group type: EXPERIMENTAL
Intervention: Training with long SOAs (350 ms) and short invalid/long valid conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with short SOA trials and probabilistic spatial contingency
Number of subjects: 0
Study: 21041570

Group type: COMPARATOR
Intervention: Warfarin anticoagulation (target international normalized ratio, 2.0 to 3.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran, 110 mg twice daily (low dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran, 150 mg twice daily (high dose)
Number of subjects: 0
Study: 18835660

Group type: EXPERIMENTAL
Intervention: Clozapine (mean modal dose: 266.7±77.9mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Olanzapine (21.2±2.5mg)
Number of subjects: 30
Study: 17910219

Group type: COMPARATOR
Intervention: Direct composite restorations on vital teeth
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Direct composite restorations on endodontically-treated teeth
Number of subjects: 84
Study: 15520691

Group type: EXPERIMENTAL
Intervention: Incremental bite advancement using a Twin-block appliance with 2 mm initial advancement and subsequent 2 mm advancements at 6 weekly intervals.
Number of subjects: 203

Group type: COMPARATOR
Intervention: Maximum bite advancement using a standard Twin-block appliance with initial bite taken edge-to-edge.
Number of subjects: 203
Study: 11581201

Group type: EXPERIMENTAL
Intervention: PCR positive for VZV DNA in temporal arteries with histologic evidence of GCA (9 out of 35 specimens, 26%)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Histologically positive temporal arteries (26 specimens) and all histologically negative arteries (29 specimens) tested negative for VZV DNA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining for VZV viral antigen IE-63 performed on 7 specimens positive for GCA and 5 negative specimens
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transmission electron microscopy (TEM) performed on 5 specimens positive for GCA
Number of subjects: 64
Study: 9463024

Group type: EXPERIMENTAL
Intervention: Ozidia
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 7936222

Group type: EXPERIMENTAL
Intervention: Aspartame (approximately 30 mg/kg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aspartame (for those 'very sure' it triggered headaches)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (for those 'very sure' it triggered headaches)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aspartame (for those 'somewhat sure' it triggered headaches)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (for those 'somewhat sure' it triggered headaches)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aspartame (for those 'not sure' it triggered headaches)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (for those 'not sure' it triggered headaches)
Number of subjects: 32
Study: 2467138

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 mg adjusted to 5.0 mg and to 10.0 mg o.d.)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg b.i.d. titrating to 160 mg b.i.d.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 30713266

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2:1 (w/v) sodium perborate paste
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Deionized water
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-thermal atmospheric plasma treatment
Number of subjects: 120
Study: 28056467

Group type: EXPERIMENTAL
Intervention: Male self-disclosure
Number of subjects: 173

Group type: COMPARATOR
Intervention: Male no self-disclosure
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Female self-disclosure
Number of subjects: 173

Group type: COMPARATOR
Intervention: Female no self-disclosure
Number of subjects: 173
Study: 25877492

Group type: COMPARATOR
Intervention: Price reduction
Number of subjects: 644

Group type: COMPARATOR
Intervention: Price reduction plus skill-building
Number of subjects: 644

Group type: COMPARATOR
Intervention: Skill-building
Number of subjects: 644

Group type: COMPARATOR
Intervention: Combined skill-building and price-reduction
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 644
Study: 24093862

Group type: EXPERIMENTAL
Intervention: Antilipemic use (pre-Part D)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Antilipemic use (post-Part D)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Lipid control (pre-Part D)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Lipid control (post-Part D)
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Post-Part D change in racial differences in antilipemic use
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Post-Part D change in racial differences in lipid control
Number of subjects: 1091
Study: 21150779

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 140
Study: 18464882

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 900 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 600 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 30
Study: 16965625

Group type: EXPERIMENTAL
Intervention: Injection drug users (IDUs)
Number of subjects: 74
Study: 14753231

Group type: COMPARATOR
Intervention: triazolam (0.25 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: zopiclone (7.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 11368289

Group type: COMPARATOR
Intervention: Risedronate 5 mg once daily
Number of subjects: 4873

Group type: COMPARATOR
Intervention: Risedronate 5 mg/day
Number of subjects: 4873

Group type: COMPARATOR
Intervention: Risedronate 5 mg/day plus estrogen
Number of subjects: 4873

Group type: EXPERIMENTAL
Intervention: Risedronate 30 mg/day
Number of subjects: 4873

Group type: EXPERIMENTAL
Intervention: Risedronate 30 mg/day for 2 months
Number of subjects: 4873

Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 4873
Study: 9463979

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8188018

Group type: COMPARATOR
Intervention: 50 micrograms Sulprostone gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 mg Gemeprost vaginal pessary
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both methods (Gemeprost and Sulprostone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gemeprost
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulprostone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual analogue scale for pain
Number of subjects: 40
Study: 3276901

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (5-fluorouracil, semustine, and vincristine)
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Postoperative BCG
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1166
Study: 31462136

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation system
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 124
Study: 30922861

Group type: EXPERIMENTAL
Intervention: Robotic-assisted endoscopic submucosal dissection (RESD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (ESD)
Number of subjects: 5
Study: 28900123

Group type: COMPARATOR
Intervention: Low intraperitoneal pressure (IPP) at 8 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warmed, humidified CO2 (WH) gas
Number of subjects: 0
Study: 26385758

Group type: EXPERIMENTAL
Intervention: Responsive neurostimulation with the RNS(®) System
Number of subjects: 0
Study: 23471930

Group type: COMPARATOR
Intervention: Basic website (health assessment with feedback and educational materials)
Number of subjects: 7706

Group type: EXPERIMENTAL
Intervention: Enhanced website (basic site features plus action planning component)
Number of subjects: 7706
Study: 21276244

Group type: EXPERIMENTAL
Intervention: OROS-MPH (54 mg/day for 8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 80
Study: 19455195

Group type: EXPERIMENTAL
Intervention: Early start dialysis (eGFR > 10 ml/min/1.73m²)
Number of subjects: 0
Study: 16675577

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 12

Group type: COMPARATOR
Intervention: NaCl 0.9% (Control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 15522644

Group type: EXPERIMENTAL
Intervention: Cervical Range of Motion Device - flexion-rotation test
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Headache severity assessment questionnaire
Number of subjects: 36
Study: 11223435

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal cholesterol levels)
Number of subjects: 40
Study: 8941054

Group type: EXPERIMENTAL
Intervention: Gestrinone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Leuprolide acetate (LA)
Number of subjects: 55
Study: 1588370

Group type: EXPERIMENTAL
Intervention: MFL (methotrexate 250 mg/m2, fluorouracil 500 mg/m2, leucovorin rescue) for 12 courses
Number of subjects: 183

Group type: COMPARATOR
Intervention: Expectancy (no chemotherapy until symptoms appeared)
Number of subjects: 183
Study: 3978356

Group type: EXPERIMENTAL
Intervention: Imagery and part of speech (nouns vs verbs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency
Number of subjects: 0
Study: 31430618

Group type: EXPERIMENTAL
Intervention: Trait self-control
Number of subjects: 0
Study: 29747575

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) and cognitive behavioural therapy (CBT) skills training
Number of subjects: 151

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 151
Study: 26686914

Group type: EXPERIMENTAL
Intervention: IUD placement at 3 weeks postpartum
Number of subjects: 201

Group type: COMPARATOR
Intervention: IUD placement at 6 weeks postpartum
Number of subjects: 201
Study: 24352969

Group type: EXPERIMENTAL
Intervention: High sulfur (HS) diet (0.67% S on a DM basis)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low sulfur (LS) diet (0.30% S on a DM basis)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low forage-to-concentrate (F:C) diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: High forage-to-concentrate (F:C) diet
Number of subjects: 16
Study: 22019792

Group type: EXPERIMENTAL
Intervention: Text messaging reminders
Number of subjects: 12
Study: 19839944

Group type: EXPERIMENTAL
Intervention: Hypothermic conditions (31-34 degrees C)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normothermic conditions (34-37.5 degrees C)
Number of subjects: 25
Study: 17664468

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² and cisplatin 75 mg/m² plus fluorouracil 750 mg/m²/d continuous infusion (DCF)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m² plus fluorouracil 1,000 mg/m²/d continuous infusion (CF)
Number of subjects: 445
Study: 16136167

Group type: EXPERIMENTAL
Intervention: 3+7+7 combination of daunorubicin, Ara‐C, and 6‐thioguanine (DAT)
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: High-dose Ara‐C during the second induction course
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Intensive consolidation chemotherapy
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Allogeneic BMT for patients with histocompatible related donors
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Allogeneic BMT for children with Down's syndrome
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: High-dose Ara‐C and multidrug resistance modulator cyclosporine
Number of subjects: 1823
Study: 12381040

Group type: EXPERIMENTAL
Intervention: Virtual spider tracking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral target tracking
Number of subjects: 0
Study: 10426601

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone sodium phosphate (0.25 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 45
Study: 9696167

Group type: EXPERIMENTAL
Intervention: Wearing a necktie by emergency physicians (EPs)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Not wearing a necktie by emergency physicians (EPs)
Number of subjects: 316
Study: 1655332

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6576814

Group type: COMPARATOR
Intervention: Immunotherapy (I)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Chemotherapy (C)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Consolidation P
Number of subjects: 217
Study: 31752212

Group type: EXPERIMENTAL
Intervention: Emergency Severity Index (ESI) triage system
Number of subjects: 240
Study: 29266398

Group type: EXPERIMENTAL
Intervention: Prograf
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Advagraf
Number of subjects: 21
Study: 27132696

Group type: COMPARATOR
Intervention: Methotrexate 3.5 g/m² on day 1 plus cytarabine 2 g/m² twice daily on days 2 and 3 (group A)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Methotrexate-cytarabine plus rituximab 375 mg/m² on days -5 and 0 (group B)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Methotrexate-cytarabine-rituximab plus thiotepa 30 mg/m² on day 4 (group C)
Number of subjects: 219
Study: 24149580

Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous remifentanil analgesia (20 mcg up to 60 mcg, lockout interval 1-2 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (0.1% bupivacaine with 2 mcg/mL fentanyl, initiation bolus 15 mL; maintenance bolus 10 mL, lockout interval 20 minutes, basal infusion 5 mL/h)
Number of subjects: 40
Study: 23050505

Group type: EXPERIMENTAL
Intervention: EAT Framework intervention based on Brief Motivational Interviewing (B-MI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study: 20135168

Group type: EXPERIMENTAL
Intervention: Low tidal volume (LTV, V(T) 7 ml/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional tidal volume (TTV, V(T) 10 ml/kg)
Number of subjects: 64
Study: 18567824

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 16
Study: 15741812

Group type: EXPERIMENTAL
Intervention: Proview phosphene tonometer
Number of subjects: 135

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 135
Study: 11919241

Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m²), ifosfamide (5 g/m² over 24 hours), and mesna (6 g/m² during ifosfamide infusion and the following 12 hours)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Bleomycin (30 units over 24 hours on day 1) followed by cisplatin (50 mg/m²), ifosfamide (5 g/m² over 24 hours), and mesna (6 g/m² during ifosfamide infusion and the following 12 hours)
Number of subjects: 303
Study: 10361863

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8522468

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trovafloxacin (all doses)
Number of subjects: 0
Study: 2022159

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine (0.2 mg/kg/hr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolus administration of ranitidine (50 mg every 4 hr)
Number of subjects: 0
Study: 7017068

Group type: EXPERIMENTAL
Intervention: (+)‐isomer of tranylcypromine (TCP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (‐)‐isomer of tranylcypromine (TCP)
Number of subjects: 20
Study: 31607719

Group type: EXPERIMENTAL
Intervention: Edaravone treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 130
Study: 27825977

Group type: EXPERIMENTAL
Intervention: Human papillomavirus testing arm (n=100) with repeated human papillomavirus testing, cytologies, and colposcopies if persistently human papillomavirus-positive.
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control arm (n=95) with random colposcopies and tests.
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Unknown persistence status (women who had human papillomavirus persistence but did not continue with repeated tests).
Number of subjects: 195